ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR241/032/SRR24149332/SRR24149332.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR241/029/SRR24149329/SRR24149329.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR241/035/SRR24149335/SRR24149335.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR241/038/SRR24149338/SRR24149338.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR241/044/SRR24149344/SRR24149344.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR241/040/SRR24149340/SRR24149340.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR241/031/SRR24149331/SRR24149331.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR241/027/SRR24149327/SRR24149327.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR241/042/SRR24149342/SRR24149342.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR241/036/SRR24149336/SRR24149336.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR241/033/SRR24149333/SRR24149333.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR241/034/SRR24149334/SRR24149334.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR241/030/SRR24149330/SRR24149330.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR241/045/SRR24149345/SRR24149345.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR241/028/SRR24149328/SRR24149328.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR241/041/SRR24149341/SRR24149341.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR241/037/SRR24149337/SRR24149337.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR241/043/SRR24149343/SRR24149343.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR241/026/SRR24149326/SRR24149326.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR241/039/SRR24149339/SRR24149339.fastq.gzprimaryOK200GenomicsGenetics, Brigham & Women's Hospital / Harvard Medical Schoolhttps://www.ebi.ac.uk/ena/browser/view/PRJNA954877Homo sapiensChIP-seq profiles of BRD4-NUT in HUES64 & HUES64 derived mesoderm (dME). ChIP-seq profiles of BRD4-NUT in Ntera-2 (NT2) cells & Ntera-2 (NT2) differentiated cells after 4 hr and 16 hr retinoic acid treatment.. Overall design: ChIP-seqxref:PubMed:37119804xref:PubMed:37131839ENAnuclear chromatin, Taf[[II]]250, Taf200, cytoplasmic chromatin, dTAF[[II]]230, TAF[[II]]250, d230, NUT midline carcinoma of the head and neck., dTAF[[II]]250, TAF[[II]]230, TFIID TAF250, cel, cell, TAF200, l(3)84Ab, dTAFII250, Taf1p, TAF[II]250, BG:DS00004.13, TAFII-250, CG17603, TAF250/230, TAF[[II]], EfW1, Cell, dTAF230, dTAF250, dmTAF[[II]]230, TAFII250, DmelCG17603, Taf250, dmTAF1, SR3-5, Taf230, p230, chromosome scaffold, TAF[[II]]250/230, TFIID, TAF, Chromatins, TAF230, TAF250, TAF1nuclear chromatin, Taf[[II]]250, Taf200, cytoplasmic chromatin, dTAF[[II]]230, TAF[[II]]250, d230, NUT midline carcinoma of the head and neck., dTAF[[II]]250, TAF[[II]]230, TFIID TAF250, cel, cell, TAF200, l(3)84Ab, dTAFII250, Taf1p, TAF[II]250, BG:DS00004.13, TAFII-250, CG17603, TAF250/230, TAF[[II]], EfW1, Cell, dTAF230, dTAF250, dmTAF[[II]]230, TAFII250, DmelCG17603, Taf250, dmTAF1, SR3-5, Taf230, p230, chromosome scaffold, TAF[[II]]250/230, TFIID, TAF, Chromatins, TAF230, TAF250, TAF1falseCell state-dependent chromatin targeting in NUT carcinomaCell state-dependent chromatin targeting in NUT carcinoma2025-09-242023-04-17PRJNA954877GSE22955896063713183937119804